Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Avita Medical ( (RCEL) ) is now available.
On August 12, 2025, AVITA Medical, Inc. entered into a placement agreement with MST Financial Services Pty Limited to offer 17,201,886 CHESS Depositary Interests to Australian institutional and professional investors. The placement is expected to raise approximately US$15 million and close on or about August 19, 2025, with the securities being exempt from registration under the Securities Act of 1933.
The most recent analyst rating on (RCEL) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.
Spark’s Take on RCEL Stock
According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.
Avita Medical’s overall stock score is primarily impacted by its financial instability, with significant net losses and negative equity. While recent corporate events and strategic partnerships offer some optimism, the stock’s valuation and technical indicators remain weak, suggesting caution for potential investors.
To see Spark’s full report on RCEL stock, click here.
More about Avita Medical
Average Trading Volume: 340,300
Technical Sentiment Signal: Sell
Current Market Cap: $149.9M
Learn more about RCEL stock on TipRanks’ Stock Analysis page.